€0 0.0 0.0%
Last Trade - 22/02/19
| Market Cap | ÂŁn/a |
| Enterprise Value | ÂŁn/a |
| Revenue | ÂŁn/a |
| Position in Universe | th / 1850 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018E | 2019E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.000 | 0.12 | 0.030 | 0.020 | 0.010 | 0.000 | |||||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
FIT Biotech Oy is a Finland-based biotechnology company that develops and licenses its patented Gene Transport Unit (GTU) vector technology for new-generation medical treatments. The Company’s GTU is a gene transport technology that solves challenge in the usability of gene therapy and deoxyribonucleic acid (DNA) vaccines. The Company primarily focuses on verifying the preclinical efficacy of its developed drug candidates (proof-of-concept). FIT Biotech Oy applies its GTU technology in seven drug development projects, including cancer (gene therapy), infectious diseases, such as human immunodeficiency virus (HIV) and tuberculosis, as well as animal vaccines.
| Last Annual | December 31st, 2017 |
| Last Interim | June 30th, 2018 |
| Incorporated | May 17, 1995 |
| No. of Shareholders: | n/a |
| No. of Employees: | n/a |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | |
| Exchange | OMX Nordic Exchange - Helsinki |
| Shares in Issue | 2,413,787,043 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | Biokatu 12, TAMPERE, 33520, Finland |
| Web | |
| Phone | +358 3 31387000 |
| Auditors | PricewaterhouseCoopers Oy |
As of 22/02/19, shares in FIT Biotech Oy are trading at €0, giving the company a market capitalisation of £n/a. This share price information is delayed by 15 minutes.
Shares in FIT Biotech Oy are currently trading at €0 and the price has moved by -92.31% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the FIT Biotech Oy price has moved by -93.05% over the past year.
There are no analysts currently covering FIT Biotech Oy.
FIT Biotech Oy is scheduled to issue upcoming financial results on the following dates:
FIT Biotech Oy does not currently pay a dividend.
FIT Biotech Oy does not currently pay a dividend.
FIT Biotech Oy does not currently pay a dividend.
To buy shares in FIT Biotech Oy you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in FIT Biotech Oy are currently trading at €0, giving the company a market capitalisation of £n/a.
Here are the trading details for FIT Biotech Oy:
We were not able to load our ranking data for FIT Biotech Oy
We were not able to load any forecast data for FIT Biotech Oy.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like FIT Biotech Oy. Over the past six months, the relative strength of its shares against the market has been -70.04%. At the current price of €0, shares in FIT Biotech Oy are trading at % against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for FIT Biotech Oy.
We were unable to find the directors for FIT Biotech Oy.
Here are the top five shareholders of FIT Biotech Oy based on the size of their shareholding:
